BioMark Diagnostics Inc.
BMKDF
$0.33
-$0.02-5.90%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -82.21% | 0.71% | -7.80% | -9.84% | -10.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -82.21% | 0.71% | -7.80% | -9.84% | -10.51% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -82.21% | 0.71% | -7.80% | -9.84% | -10.51% |
| SG&A Expenses | -34.91% | -47.85% | 27.87% | -10.12% | 15.20% |
| Depreciation & Amortization | 47.42% | 72.04% | 111.36% | -42.74% | -36.89% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.67% | -34.05% | 18.16% | -29.41% | 32.68% |
| Operating Income | 17.61% | 36.34% | -20.39% | 31.34% | -37.12% |
| Income Before Tax | 12.91% | 33.98% | -1.31% | 20.00% | -155.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.91% | 33.98% | -1.31% | 20.00% | -155.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.91% | 33.98% | -1.31% | 20.00% | -155.77% |
| EBIT | 17.61% | 36.34% | -20.39% | 31.34% | -37.12% |
| EBITDA | 17.75% | 36.63% | -20.54% | 31.76% | -37.33% |
| EPS Basic | 25.00% | 42.00% | 17.65% | 91.43% | -131.58% |
| Normalized Basic EPS | 25.00% | 41.94% | 19.05% | 90.91% | -133.33% |
| EPS Diluted | 25.00% | 42.00% | 17.65% | 91.43% | -131.58% |
| Normalized Diluted EPS | 25.00% | 41.94% | 19.05% | 90.91% | -133.33% |
| Average Basic Shares Outstanding | 15.63% | 15.63% | 23.29% | 938.55% | 9.13% |
| Average Diluted Shares Outstanding | 15.63% | 15.63% | 23.29% | 938.55% | 9.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |